The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: Critical Outcome Technologies

Monday Deal Review: February 24, 2014

  Welcome to your Monday Biotech Deal Review for February 24, 2014!

Read more of this post

Monday Deal Review: February 10, 2014

  Welcome to your Monday Biotech Deal Review for February 10, 2014! The big news this week was Valeant’s proposed acquisition of another skin care innovator, PreCision Dermatology, for $475 million. Hit the break for more details on this as well as the rest of the week’s major biotech news.

Read more of this post

Monday Deal Review: November 4, 2013

  Welcome to your Monday Biotech Deal Review for November 4, 2013! A number of financings have closed in the past week, with a few more placement being announced as well.  Prometric is continuing with its public offering, while OPMEDIC is continuing with its amalgamation which will take the company private.

Follow the link to see the full week’s worth of major biotech stories!

Read more of this post

Monday Deal Review: September 9, 2013

Welcome to your Monday Biotech Deal Review for September 9, 2013! This week saw Medicago recieve the shareholder approval it needed in order to continue its arrangement with MTPC.  Cash consideration of $1.16 will be given for each share of Medicago.

For more detail on this deal, as well as the rest of the major recent biotech stories, hit the break!

Read more of this post

Monday Deal Review: June 24, 2013

Welcome to your Monday Biotech Deal Review for June 24, 2013!

The past weeks’ big news is Antibe’s IPO, which resulted in approximately $2.1 million in proceeds. Antibe also concurrently made a private placement of shares with two private investors.

Valeant also made big news with the announcement of a public offering for proceeds of $1.75 billion, and a senior notes offering of about $3.2 billion.

Get the details on these major stories, and many more, by following the break.

Read more of this post

Monday Deal Review: February 4, 2013

Welcome to your Monday Biotech Deal Review for February 4, 2013! This week saw significant activity in the sector generally  On the M&A side, Valeant continued their ongoing acquisition strategy, buying the Russian Natur Product International, a primarily OTC private pharma company. Gilead’s acquisition of YM Biosciences took one step closer to completion as YM shareholders approved the statorily mandated vote to approve the plan of arrangement that will facilitate the arrangement. Court approval is now required as one of the final steps. Microbix was also involved in the week’s M&A activity, having sold its water for injections business to Irvine Scientific. The there was also significant investment activity this week, including Biosenta announcing a new private placement.

See detail on these and the the rest of the week’s major biotech stories by clicking through!

Read more of this post

Monday Deal Review: December 10, 2012

Welcome to your Monday Biotech Deal Review for December 10, 2012.  This week saw significant activity in the commercial and licensing agreements arena, as well as a couple M&Eh transactions. Of particular note is Valeant’s commercial resolution of their ongoing issues with Gladerma SA stemming from Valeant’s recent purchase of Medicis.  On the M&A side of things, Biosign has purchased their exclusive distributor Bioanalytics Inc. hot on the heels of closing their recent private placement, which closed the previous week. See the rest of a relatively busy past week’s major biotech deals by clicking through!
Read more of this post

Monday Biotech Deal Review: April 30, 2012

Welcome to your Monday Biotech Deal Review for April 30, 2012.  It was a slow week last week, with a couple of private placement closings, a business unit purchase and some commercial activity.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: April 16 2012

Welcome to your Monday Biotech Deal Review for April 16, 2012. Highlights include deals by Bioniche, Valeant and Bunge and $5 million of equity financings.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: April 2, 2012

Welcome to your Monday Biotech Deal Review for April 2, 2012.  There have been few large transactions over the previous weeks, but there have been some private placement financings and M&A activity, including the announcement of a takeover by Valeant of Russian-based Natur Product International for approximately $180M.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: May 2, 2011

Welcome to your Monday Biotech Deal Review for May 2, 2011.  This review is a double feature from last week’s Easter break.  Plenty happened in the interim, with Angiotech developments, private placements, licensing and other interesting corporate transactions and announcements.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: April 18, 2011

Welcome to your Monday Biotech Deal Review for April 18, 2011.  Just by way of FYI, readers may be interested to know that The Canadian Institute will be hosting its 5th annual conference on Drug Pricing and Reimbursement in Canada in Toronto from June 14 – 15 at the Sutton Place Hotel.  The conference aims to bring key stakeholders together to share perspectives and strategies on maintaining competitiveness and compliance in these difficult markets.  Stay tuned on crossborderbiotech for coverage from the conference.  Back to the deal review, there was a fair bit of commercial activity last week, with some interesting licensing and commercial transactions announced or closed.  Read on to learn more.     Read more of this post

Monday Biotech Deal Review: April 11, 2011

Welcome to your Monday Biotech Deal Review for April 11, 2011.  Notable events in the Canadian biotech space over the past week included: (i) the filing by Valeant with the SEC of a consent solicitation statement in furtherance of its efforts to replace the board of its hostile target Cephalon; (ii) the approval by creditors of the plan put forward by Angiotech in respect of its restructuring and the sanctioning of the plan by courts in Canada and the U.S.; (iii) the closing of a $34.5M private placement by MethylGene; and (iv) the resignation of the board of directors of Ambrilia and the seeking by Ambrilia to pursue insolvency proceedings under the Bankruptcy statute as opposed to creditor protection under the CCAA.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: March 29, 2011

Welcome to your Monday Biotech Deal Review for March 28, 2011.  There was a flurry of financing activity last week, with over $76M raised or announced in biotech funds (not including the $60M Genome Canada investment announced by the Government of Canada).  Double-digit million-dollar deals included MethylGene’s $34.5M private placement announcement, Medicago’s $17M private placement announcement, and the closing of Novadaq’s $15M private placement.  Read on to learn more.  Read more of this post

Monday Biotech Deal Review: January 10, 2011

Welcome to your Monday Biotech Deal Review.  2011 is off to a fast start in Canadian biotech!  Among other things, last week’s highlights included some interesting licensing activity, the completion by Bioniche of its A$12.5 million Australian offering, a $200k SEDA draw-down by Allon Therapeutics, Futuremed’s conversion to a corporation, and some regulatory and litigation updates as well.  Read on to learn more.

Monday Biotech “Happy Holidays” Deal Review: December 27, 2010

Welcome to your Monday Biotech “Happy Holidays” Deal Review!  For those who may have noticed, last week the Monday Biotech Deal Review took its own holiday, so this week’s digest contains biotech news spanning the past two weeks – to ensure you don’t miss a single drummer boy’s beat.  It has been a busy two weeks, with a notable $40M public offering by YM BioSciences of common shares that was announced, priced and closed, as well as an update by Angiotech with respect to its debt restructuring efforts.  There have also been some interesting strategic partnerships and licensing activity over the break.  Read on to learn more.     Read more of this post

Monday Biotech Deal Review: November 22, 2010

Welcome to your Monday Deal Review.  There was quite a bit of Canada / U.S. crossborder investment activity last week, with a $700M note offering by Valeant, IMRIS’ USD$52M public offering, and both IMRIS and Tekmira announcing their listing on the NASDAQ.   Read on to learn more, as well as the usual summaries of recent biotech activity. Read more of this post

Monday Deal Review: November 1, 2010

Welcome to the Monday Deal Review for November 1, 2010.  This week’s review contains the news of a possible recapitalization of Angiotech, following its deferral of interest payments on 7.75% Senior Subordinated Notes due October 1, 2010.  Read on to learn more, as well as other happenings from last week’s biotech scene. Read more of this post

Monday Biotech Deal Review: July 5, 2010

Not a bad week for deals, considering the holiday weekend in both Canada and the U.S.. Response Biomedical placed a PIPE with OrbiMed funds, CTI did a follow-on round in Zymeworks and LAB Research took an equity line. Plus a companion diagnostic deal from Aeterna, just as I’m planning for Diagnostics Asia in August. The week’s rounded out with $450k from the NRC and a spin-out from Ondine. Read more of this post

Monday Biotech Deal Review: May 31, 2010

Things are picking up a bit this week, with a few new financings, some collaboration agreements and a deal in the venture capital community that coincided with the CVCA’s annual meeting. Read more of this post

Monday Biotech Deal Review: May 10, 2010

Some people were on the move this week — not only did Sanofi Canada announce 70 R&D job cuts, but BioMS took on a new banker and Labopharm, CardioComm and GeneNews all get new faces. Despite the fact that it seemed half of the country’s companies and deal-makers were at BIO in Chicago this week, there was still a fair amount of positive deal activity including numerous private placements, commercial agreements and a bit of M&Eh.

Read more of this post

Monday Biotech Deal Review: May 3, 2010

I guess the excitement of BIO was driving deals this week. To the delight of the economic development folks, government was in on the action — Ontario announced a BIP investment and announced a whole new strategy, and OICR funded three equity deals. The private sector was also out in force, with four new licensing deals (including some interesting structures) and more securities than the week might otherwise … warrant. Keep reading after the jump…

Monday Biotech Deal Review: February 22, 2010

There was a lot of follow-up among Canadian biotech deals this week: letters of intent turning into definitive agreements, merged companies turning to consolidation, bids launched on schedule and wrapped up; as well as an average crop of new M&Eh and securities.  Start things off with an interesting (cross-border!) twist to the SIFT/SR&ED deals we’ve seen after the jump…

Follow

Get every new post delivered to your Inbox.

Join 131 other followers